未登录

D

Dinko Rekić

AstraZeneca AB R&D

H指数:12

被引数:762

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Case Study of Model-Informed Drug Development of a Novel PCSK9 Antisense Oligonucleotide. Part 2: Phase 2 to Phase 3

模型指导药物开发的案例研究：一种新型PCSK9反义寡核苷酸。第二部分：从II期到III期

cpt pharmacometrics systems pharmacology

IF0

2025-08-050

OAAI

Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-11-050

OAAI

Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-03-192

OA

Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-01-022

PRE

A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2022-10-016

OAAI

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-06-1010

OAAI

Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-09-285

OAAI

An oral antisense oligonucleotide for PCSK9 inhibition

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2021-05-1289

PRE

Gennemark, Peter; Walter, Katrin; Clemmensen, Niclas; Rekic, Dinko; Nilsson, Catarina A. M.; Knochel, Jane; Holtta, Mikko; Wernevik, Linda; Rosengren, Birgitta; Kakol-Palm, Dorota; Wang, Yanfeng; Yu, Rosie Z.; Geary, Richard S.; Riney, Stan J.; Monia, Brett P.; Isaksson, Rikard; Jansson-Lofmark, Rasmus; Rocha, Cristina S. J.; Linden, Daniel; Hurt-Camejo, Eva; Crooke, Rosanne; Tillman, Lloyd; Ryden-Bergsten, Tina; Carlsson, Bjorn; Andersson, Ulf; Elebring, Marie; Tivesten, Anna; Davies, Nigel

Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study Lin

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Assumption Checking Before Application of the Prespecified QT Linear Mixed Effect Model is Essential

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2020-06-081

OAAI

In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2017-09-0164

OAAI

Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis

ANNALS OF THE AMERICAN THORACIC SOCIETY

IF5.4

2017-09-01132

PREAI

Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2017-09-0147

OAAI

External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients

IF3.7

2012-12-073

OAAI

Bilirubin-A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy

IF3.7

2011-09-1315

OAAI

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2011-03-1147

OAAI

Toxicokinetics of Mercury after Long-Term Repeated Exposure to Thimerosal-Containing Vaccine

TOXICOLOGICAL SCIENCES

IF4.1

2011-01-2042

OAAI